Meyka Pro banner
biote Corp.

biote Corp. Fundamental Analysis (NASDAQ: BTMD)

BTMD●NASDAQ
HealthcareMedical - Care Facilities
$1.08
$0.03(2.70%)
U.S. Market opens in 1h 11m

biote Corp. Fundamental Analysis (NASDAQ: BTMD)

biote Corp. (NASDAQ: BTMD) shows weak financial fundamentals with a PE ratio of -13.22, profit margin of -1.08%, and ROE of 3.13%. The company generates $0.3B in annual revenue with weak year-over-year growth of -2.52%.

Key Strengths

Cash Position30.19%
PEG Ratio0.12

Areas of Concern

ROE3.13%
Operating Margin5.02%
We analyze BTMD's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 46.6/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

D
46.6/100

We analyze BTMD's fundamental strength across five key dimensions:

Efficiency Score

Weak

BTMD struggles to generate sufficient returns from assets.

ROA > 10%
-1.89%

Valuation Score

Excellent

BTMD trades at attractive valuation levels.

PE < 25
-13.22
PEG Ratio < 2
0.12

Growth Score

Weak

BTMD faces weak or negative growth trends.

Revenue Growth > 5%
-2.52%
EPS Growth > 10%
8.34%

Financial Health Score

Excellent

BTMD maintains a strong and stable balance sheet.

Debt/Equity < 1
-1.96
Current Ratio > 1
1.37

Profitability Score

Weak

BTMD struggles to sustain strong margins.

ROE > 15%
3.13%
Net Margin ≥ 15%
-1.08%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is BTMD Expensive or Cheap?

P/E Ratio

BTMD trades at -13.22 times earnings. This suggests potential undervaluation.

-13.22

PEG Ratio

When adjusting for growth, BTMD's PEG of 0.12 indicates potential undervaluation.

0.12

Price to Book

The market values biote Corp. at -0.45 times its book value. This may indicate undervaluation.

-0.45

EV/EBITDA

Enterprise value stands at -4.80 times EBITDA. This is generally considered low.

-4.80

How Well Does BTMD Make Money?

Net Profit Margin

For every $100 in sales, biote Corp. keeps $-1.08 as profit after all expenses.

-1.08%

Operating Margin

Core operations generate 5.02 in profit for every $100 in revenue, before interest and taxes.

5.02%

ROE

Management delivers $3.13 in profit for every $100 of shareholder equity.

3.13%

ROA

biote Corp. generates $-1.89 in profit for every $100 in assets, demonstrating efficient asset deployment.

-1.89%

Following the Money - Real Cash Generation

Operating Cash Flow

biote Corp. generates limited operating cash flow of $22.72M, signaling weaker underlying cash strength.

$22.72M

Free Cash Flow

biote Corp. produces free cash flow of $12.04M, offering steady but limited capital for shareholder returns and expansion.

$12.04M

FCF Per Share

Each share generates $0.27 in free cash annually.

$0.27

FCF Yield

BTMD converts 15.27% of its market value into free cash.

15.27%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-13.22

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.12

vs 25 benchmark

P/B Ratio

Price to book value ratio

-0.45

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.27

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-1.96

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.37

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.03

vs 25 benchmark

ROA

Return on assets percentage

-0.02

vs 25 benchmark

ROCE

Return on capital employed

0.13

vs 25 benchmark

How BTMD Stacks Against Its Sector Peers

MetricBTMD ValueSector AveragePerformance
P/E Ratio-13.2231.47 Better (Cheaper)
ROE3.13%507.00% Weak
Net Margin-1.08%-4103644.00% (disorted) Weak
Debt/Equity-1.960.00 Distorted
Current Ratio1.375.79 Neutral
ROA-1.89%-262.00% (disorted) Weak

BTMD outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews biote Corp.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-60.07%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-77.55%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-67.75%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ